Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles

A central challenge in nanomedicine is the scalable and precise engineering of nanocarriers that are simultaneously tunable, immune-compatible, and capable of encapsulating diverse bioactive cargos. Extracellular vesicles (EVs), including native red blood cell-derived EVs (RBCEVs), offer biocompatibility but remain limited by heterogeneous composition, low yield, poor scalability, and limited control in cargo loading. Here, we introduce a bottom-up strategy for developing engineered red blood cell extracellular vesicles (eRBCEVs) through microfluidic diffusional mixing of purified RBC lipids and components. Parametric optimization through multi-physics simulation enabled predictive control over flow rates, lipid concentration, and channel geometry. eRBCEVs exhibited comparable encapsulation efficiency across molecular cargos of distinct sizes and properties, including oligonucleotides, gold nanoparticles, hemoglobin, erythrocruorin (∼3.6 MDa), and full adeno-associated virus (AAV ∼25 nm) particles, validated through cryo-EM, chemical mapping, and high-resolution TIRFM. Surface conjugation with CD47 peptide was established for comparison with RBCEVs; the bio-conjugations with α-PD-L1 antibodies yielded functionalized vesicles with uptake in PD-L1-positive human tumor organoids. In vivo biodistribution and pharmacokinetic analysis in mice demonstrated sustained circulation and tissue distribution in the liver, spleen, and lungs. Neutrophil activation and macrophage uptake assays confirmed minimal immunogenicity compared to conventional particles and free-protein controls. Collectively, our platform enables the scalable synthesis of customizable eRBCEVs that preserve RBC lipid features, support cargo flexibility, and potential for scale-up. This work establishes eRBCEVs as a next-generation therapeutic platform for programmable, patient-specific delivery in gene therapy, immunomodulation, and translational nanomedicine.

Authors

Institutions

Publication Details

Journal
Advanced Healthcare Materials
Published
2026-07-16
DOI
https://doi.org/10.1002/adhm.202504351
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles

Kim Truc Nguyen, Xilal Y. Rima, Ajeet Singh, Willa A. Hsueh et al.
Advanced Healthcare Materials
Extracellular vesicles in disease
article

Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles

Kim Truc Nguyen, Xilal Y. Rima, Ajeet Singh, Willa A. Hsueh, Nicholas R. Merriam, Dharti Shantaram, Setty M. Magaña, Hui Li, Scott Q. Harper, Nizar Y. Saad, Blaise R. Kimmel, Zachary D. Schultz, Eduardo Reátegui, Jacob Doon‐Ralls, Chiranth K. Nagaraj, Xin Huang, Courtney Culkins, ANASTASIIA AMARI, Alejandro Bresolin, Rachel E. Kopec, Mangesh D. Hade, Andre F. Palmer, Vahedi Amid, Nana Boateng
article en

Abstract

A central challenge in nanomedicine is the scalable and precise engineering of nanocarriers that are simultaneously tunable, immune-compatible, and capable of encapsulating diverse bioactive cargos. Extracellular vesicles (EVs), including native red blood cell-derived EVs (RBCEVs), offer biocompatibility but remain limited by heterogeneous composition, low yield, poor scalability, and limited control in cargo loading. Here, we introduce a bottom-up strategy for developing engineered red blood cell extracellular vesicles (eRBCEVs) through microfluidic diffusional mixing of purified RBC lipids and components. Parametric optimization through multi-physics simulation enabled predictive control over flow rates, lipid concentration, and channel geometry. eRBCEVs exhibited comparable encapsulation efficiency across molecular cargos of distinct sizes and properties, including oligonucleotides, gold nanoparticles, hemoglobin, erythrocruorin (∼3.6 MDa), and full adeno-associated virus (AAV ∼25 nm) particles, validated through cryo-EM, chemical mapping, and high-resolution TIRFM. Surface conjugation with CD47 peptide was established for comparison with RBCEVs; the bio-conjugations with α-PD-L1 antibodies yielded functionalized vesicles with uptake in PD-L1-positive human tumor organoids. In vivo biodistribution and pharmacokinetic analysis in mice demonstrated sustained circulation and tissue distribution in the liver, spleen, and lungs. Neutrophil activation and macrophage uptake assays confirmed minimal immunogenicity compared to conventional particles and free-protein controls. Collectively, our platform enables the scalable synthesis of customizable eRBCEVs that preserve RBC lipid features, support cargo flexibility, and potential for scale-up. This work establishes eRBCEVs as a next-generation therapeutic platform for programmable, patient-specific delivery in gene therapy, immunomodulation, and translational nanomedicine.

Advanced Healthcare Materials
Nationwide Children's Hospital (US), The Ohio State University Wexner Medical Center (US), The Ohio State University (US)
Industry, innovation and infrastructure
Openalex Percentile: Top 13%
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.